AstraZeneca (AZN) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
30 Oct, 2026Executive summary
9M Total Revenue was $46.881bn, up 7% at CER; Core EPS rose 14% to $8.00, supported by broad therapy-area growth.
Twelve positive Phase III readouts and four first approvals advanced the pipeline; 2027 readouts represent >$20bn in combined non-risk-adjusted peak-year revenue potential.
Ambition 2030 remained on track, with an $80bn risk-adjusted Total Revenue target and 20 NMEs by 2030.
Financial highlights
9M Product Revenue was $46.768bn, up 6% at CER; Alliance Revenue rose 32% to $2.8bn. Q3 Total Revenue was $16.209bn, up 7%.
9M reported operating profit rose 10% to $11.797bn; Core operating profit increased 14% to $16.365bn.
9M reported EPS was $5.62, up 11%; Core EPS was $8.00, up 14%. Q3 Core EPS rose 19% to $2.79.
Core gross margin was 83% for 9M and 82% in Q3; 9M reported and core tax rates were 18% and 19%, respectively.
9M operating cash inflow was $10.9bn, down $1.3bn; working capital, higher tax payments and FX effects outweighed higher operating profit. CapEx was $2.3bn.
Outlook and guidance
FY 2026 guidance was reiterated: Total Revenue growth at a mid-to-high single-digit percentage and Core EPS growth at a low double-digit percentage, at CER.
Core tax rate is expected at 18–22%; core gross margin is expected to be stable to slightly better than 2025.
Core R&D expense is expected at the upper end of the low-20% range of Total Revenue; operating expenses are expected to step up sequentially in Q4.
FY 2026 CapEx is expected to rise by a low-teens percentage, driven by manufacturing expansion and technology investment.
More than 20 key Phase III readouts and pivotal data for nine potential new medicines are expected in 2027; non-risk-adjusted peak-year potential exceeds $20bn.
Latest events from AstraZeneca
- ESMO results strengthened oncology prospects, with an $80bn 2030 revenue ambition.AZN
Investor update - FY 2023 revenue rose 6% and Core EPS 15%, with FY 2024 double-digit growth guided.AZN
Q4 2023 - HICKORY missed its primary endpoint; efzimfotase alfa retains $3B–$5B peak-sales potential.AZN
AZN Meet The Management at ASBMR 2026 - Tozorakimab reduced COPD exacerbations by up to 34% in Phase III, supporting major growth targets.AZN
Investor update - H1 2026 revenue up 6% CER, Core EPS up 11%, driven by Oncology and Rare Disease growth.AZN
Q2 2026 - Ambitious 2030 targets drive emissions cuts, health equity, and innovation in sustainability.AZN
Investor update - Q1 2026 saw 13% revenue growth, strong Oncology and Rare Disease gains, and reaffirmed guidance.AZN
Q1 2026 - Q1 2025 revenue up 10% at CER, Core EPS up 21%, guidance reaffirmed.AZN
Q1 2025 - 2024 revenue up 21% to $54.1bn, core EPS up 19%, with strong growth and robust 2025 outlook.AZN
Q4 2024